CDC ENTEBBE

Patritumab deruxtecan showed significant PFS improvement in EGFR-mutated NSCLC patients post-TKI treatment, outperforming standard platinum-based doublet chemotherapy in the HERTHENA-Lung02 trial. Daiichi Sankyo and Merck plan to discuss these findings with regulatory authorities.

New study supports Hunan Seafood Wholesale wet market in Wuhan as origin of COVID-19 pandemic, with evidence of animal species known to carry the virus present in the market.

Kaiser Permanente study finds 14% of people with chronic fatigue-like syndrome developed it after COVID, with ongoing research to explore the relationship between COVID and ME/CFS.

Oregon State University researchers received a $1.2 million NIH grant to develop an AI-powered device using saliva analysis for personalized epilepsy treatment, aiming to optimize anti-seizure medication dosing and reduce side effects.

The House of Representatives passed the BIOSECURE Act (HR 8333) with a 306-81 vote, exceeding the required two-thirds majority. The bill, unamended from the House Committee version, aims to prohibit executive agencies from contracting with entities using biotechnology equipment or services from 'companies of concern.' The Act names specific biotechnology firms with alleged ties to foreign adversaries, sparking debate over due process and supply chain impacts. The House bill includes mitigating provisions such as an eight-year grandfathering window, a safe harbor provision, and a waiver program, aiming to ease transition for affected companies.

Oregon State University researchers, with a $1.2 million NIH grant, aim to develop an AI-powered device using saliva for personalized epilepsy treatment, optimizing anti-seizure drug dosing.

FDA approves Sanofi and AstraZeneca's new filling line for Beyfortus, enabling expanded manufacturing capacity and supply in the U.S. for the 2024/2025 RSV season. Beyfortus, a long-acting antibody, was FDA-approved in July 2023 for infants and children up to 24 months old at severe risk of RSV infection. CDC analysis in March 2024 showed Beyfortus 90% effective at preventing RSV hospitalization.

Providence Health Plan and American Heart Association launch Embracing Community Care, a 3-year cardiovascular health initiative in Oregon and Washington, starting with POIC. The program provides blood pressure measurement kits and education, aiming to improve awareness and health in underserved communities.